M2GEN’s ORIEN Avatar data product is the first solution to build comprehensive genotypic and phenotypic profiles of consenting cancer patients while shielding the patient’s identity behind an avatar.  ORIEN Avatar tracks patient clinical progressions over their lifetime to provide the richest data source for targeted cancer therapy advancement.  ORIEN Avatar data solution is optimized for oncology research by providing integrated longitudinal clinical data and whole exome, transcriptome and germline sequencing around consented oncology patients.  ORIEN Avatar enables the development of advanced cohorts based on nuanced aspects of patients’ disease including biomarkers, mutations, tumor normal, treatment progressions, recurrences and more.

M2GEN’s Zenith data solution includes data from tumor specimens collected between 2006 and 2012 via our partnership with Moffitt Cancer Center and community hospitals. This targeted solution creates a clear picture of more than 30 disease types in early and late stages with longitudinal clinical data from 18,000 patients and molecular data from 16,000 patients.

Lyncis is M2GEN’s most narrowly targeted data solution, focusing exclusively on melanomas as well as cancers of the lung, colon, and pancreas. Collected between 2011 and 2015 via the ORIEN network, this dataset includes longitudinal clinical data as well as whole exome sequencing and RNA sequencing of molecular data.

Cohort studies are a critical part of discovering novel cancer therapies, enabling researchers to zero in on key factors impacting disease development and progression as well as treatment efficacy. M2GEN’s unrivaled and ever-expanding cache of patient data allows us to build a wide array of active cohorts based on specific sets of criteria. This highly targeted molecular and longitudinal clinical data can be leveraged for everything from accelerating treatment development and regulatory and safety research to bringing new therapies to market.

M2GEN’s patented Total Cancer Care^® (TCC) protocol is a powerful tool that has allowed us to create the most comprehensive consented patient registries available. The TCC Active Directory puts this unique protocol to its best use by enabling our partners to design observational studies around active patient cohorts.  This active approach to data generation enables the creation of advanced cohorts and the close study of treatment efficacy and outcomes over the course of patients’ lifetimes.

Cancer research is incredibly varied and complex, requiring enormous quantities of data to advance the field. However, raw data alone isn’t enough to drive innovations and bring about new therapies. M2GEN’s biomedical informatics service makes use of the clinical and molecular data gathered through our Total Cancer Care^® protocol to deliver advanced, structured, and targeted real-world data and analysis. Our services are tailored to the specific research being conducted by our pharmaceutical partners, giving them the tools they need to develop revolutionary cancer treatments.

Through the Total Cancer Care^® protocol and ORIEN^® network, M2GEN can assist in the identification and matching of patients for clinical trials, aid in patient recruiting, development of in-silico external control arms, treatment protocol focused expanded access programs or rescuing trials in jeopardy. Our optimized site activation protocols, including submissions to a single internal review board (sIRB) and scientific review committee, help to accelerate enrollment and activation. Additionally, M2GEN partners can leverage our expertise in biomedical informatics and data collection to assist with clinical trial design.

As an oncology-focused informatics company, M2GEN has the molecular pipeline analytical services and intellectual resources to coordinate and assist novel research leveraging our ORIEN network. Our services are flexible, allowing us to work closely with our partners and develop solutions that are targeted to their specific area of research. From comprehensive research coordination services to custom bioinformatics, we offer solutions to overcome the most difficult cancer research obstacles.